UK DELEGATES

BrIgID Bio is a biotech spin-out from the University of Aberdeen, developing novel, first in class antibody-based drugs as safer and efficacious treatment solutions for highrisk and drug resistant fungal infections

The BrIgID team brings a unique combination of globally recognized scientific expertise in fungal cell wall biosynthesis, antifungal drug resistance, antibody engineering, pre-clinical drug development and commercial experience in biotech partnering, product launch and exit.

Contact:
Dr. Soumya Palliyil – CEO & Co-Founder
Phone: +44 (0)7793 601366
Email: soumyapalliyil@brigidbio.com
Website: www.brigidbio.com
Industry: Drug discovery and development

Cytecom is developing a rapid diagnostic test using their patented optical electrophysiology technology to reduce the time for targeted antibiotic selection from days to seconds.

With the recent endorsement of a £1.5 million UK government contract, Cytecom is bringing a new era of antimicrobial susceptibility testing. Promising to transform patient care and confront the global threat of AMR, Cytecom is looking for Swiss partners.

Contact:
Dr. Magdalena Karlikowska – CEO
Phone: +44 (0)7776 336146
Email: m.karlikowska@cytecom.co.uk
Website: www.cytecom.co.uk
Industry: Medical diagnostics

Evolvere Biosciences is developing a precision antibiotics platform oriented around dual revenue from therapeutic assets and licensed AI tools. They developed a new modality of protein antibiotic therapies that prevent bacterial drug resistance and precisely target pathogenic bacteria, without harming commensal microbes or human cells.

Founded in 2021 by a team of engineers and biologists from Oxford, the company leverages expertise in bioengineering, AI, and evolutionary biology. Their platform subjects large libraries
of antibiotic candidates to iterative rounds of mutation and selection for enhanced antibacterial activity and resistance minimization.

Contact:
Adam Winnifrith – CEO & Co-Founder
Phone: +44 (0)7401 700405
Email: adamwinnifrith@evolverebiosciences.com
Website: www.evolverebiosciences.com
Industry: TechBio and Therapeutic Development

Over 250 million times a year we expect our doctors to treat us for infections without knowing the cause, nor the most effective treatment. At FluoretiQ, they develop fast and accurate diagnostics that can be used at the point of care, to help clinicians make their first antibiotic prescription, the right antibiotic prescription.

This year FluoretiQ are launching VERI-5: a compact hardware and single use cartridge system to quickly detect bacteriuria at the point of care. Please contact James Preece (j.preece@fluoretiq.com) if your organisation would be interested in joining their early access program.

Contact:
James Preece – Product Manager
Phone: +44 (0)7531 800932
Email: j.preece@fluoretiq.com
Website: www.fluoretiq.com
Industry: Medical diagnostics

Glox Therapeutics is developing precision antibiotics based on engineered protein bacteriocins, which are potent narrowspectrum antibiotics.

Relative to wild-type bacteriocins, the engineering strategies will reduce the frequency of resistance development, provide a route to new IP, enhance species coverage and enable building of bacteriocins designed to target Gram-negative pathogens of choice.

Contact:
Dr. James Clark – CEO
Phone: +44 (0)7592 659711
Email: j.clark@gloxtherapeutics.com
Website: www.gloxtherapeutics.com
Industry: Biotechnology

LightOx develops new light activated treatments for infection in wounds.

LightOx have developed a new class of drug compound that is capable of being directly applied to a wound, ulcer or surgical site and targets microbial species that cause complications and lengthen the wound healing recovery time.

Contact:
Sam Whitehouse – CEO
Phone: +44 (0)7867 531431
Email: sam.whitehouse@lightox.co.uk
Website: www.lightox.co.uk
Industry: Drug development / wound care

Medusa Pharmaceuticals is an Imperial College London spinout, developing innovative synergistic combinations of repurposed drugs to overcome antimicrobial resistance (AMR).

Rather than trying to discover a new drug (which can be prohibitively expensive and high risk, particularly in the absence of a clear pricing and reimbursement model), Medusa Pharmaceuticals is developing a novel approach to tackle this substantial and rising threat.

Contact:
James Duboff – Co-founder & CEO
Email: james@medusapharma.com
Website: www.medusapharma.com
Industry: Pharmaceuticals

Microbira has created an Artificial Intelligence-driven solution to microorganism identification – the Microbira Advanced Analytical Platform Infrared, (MAAP-IR).

Microbira’s platform is cost effective, compact and reagent free decreasing the overall cost
of microbial testing but also aligns with carbon footprint reduction policies by eliminating the environmental costs of plastic disposables.

Contact:
Marianne Laing Ismail – CEO
Phone: +44 (0)7768 503788
Email: mismail@microbira.com
Website: www.microbira.com
Industry: Healthcare diagnostics

Oppilotech’s modelling allows accurate mapping of cellular biochemistry at extremely high levels of resolution, which is utilised to identify the best drug targets whilst also confirming that cells cannot bypass their inhibition.

Their team is made up of a range of experienced scientists with experience in biochemistry, microbiology, med chem, antimicrobial drug development and AI/ML, as well as corporate functionality. Keen to collaborate, they are looking to advance their work

Contact:
Ed Siegwart – Dir. of Microbiology
Phone: +44 (0)7975 683998
Email: ed.siegwart@oppilotech.com
Website: www.oppilotech.com
Industry: Biotech

Oxford SimCell Ltd. is a biotechnology spinout from the University of Oxford developing vaccines against antimicrobial resistant bacteria.

SimCells® are genome-free bacteria produced by switchable expression of a nuclease that cuts the bacterial genome. This process renders the host bacteria unable to replicate, but preserves important immunogenic cell surface features. SimCells cannot grow but are otherwise identical to their living counterparts, and so are ideal for use as inactivated whole-cell vaccines.

Contact:
Joseph Kennerley – Chief Scientific Officer
Phone: +44 (0)7428 848851
Email: joseph.kennerley@oxfordsimcell.com
Website: www.oxfordsimcell.com
Industry: Biotechnology

UK SME Phytoceutical have developed novel lipid core nano micellar technology improving bioactive delivery. Patents are granted in the EU and UK.

The company is developing BioXicol to modify the tissue microenvironment disrupting biofilms with secondary healing, combatting Antimicrobial Resistance (AMR) without the use of existing antibiotics.

Contact:
William Buchanan – Director
Phone: +44 (0)7718 317056
Email: will@phytoceutical.co.uk
Website: www.phytoceutical.co.uk
Industry: BioScience

RapidX Bio is a Cambridge (UK)-based molecular diagnostic startup aimed at building rapid point-of-care qPCR machines testing for a wide range infectious diseases.

Powered by nanotechnology, RapidX machines are being developed for multiplexing up to 12 genetic targets in under 5 minutes, for bacteria as well as viruses. Some of these targets may be used for genotypic antimicrobial susceptibility testing.

Contact:
Emilien Chapelon – Founding Biologist
Phone: +33 698161646
Email: emilien@rapidx.bio
Website: www.RapidX.bio
Industry: Biotech: Molecular diagnostics/antibiotic susceptibility testing (AST)

Rostra Therapeutics is an early-stage company with a mission to develop a novel molecular platform technology into medicines to treat infectious diseases and help address the global threat of AMR.

Rostra Therapeutics aims to develop its multi-targeted lead molecules into medicines to treat life threatening Invasive Fungal Diseases in immunocompromised patients, and other infections where treatments and patient well being are compromised by AMR.

Contact:
David Findlay – CEO
Phone: +44 (0)7879 694137
Email: david.findlay@rostratx.com
Website: www.rostratx.com
Industry: Lifescience

Veraco is revolutionising how healthcare spaces combat the silent threat of environmental contamination. Their antimicrobial touchpoint surfaces stand guard against the spread of bacteria.

Veraco is for everyone, and that is their mission. They are for hospitals, care homes, offices, schools, and everything inbetween. They believe every touchpoint deserves protection, and their adaptable solutions fit seamlessly into any environment

Contact:
Charles Churchman – Director
Phone: +44 (0)7787 551496
Email: charles@veraco.co.uk
Website: www.veraco.co.uk
Industry: Antimicrobial Surfaces